Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
about
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraVon Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpuraConcomitant thrombotic thrombocytopenic purpura and ANCA-associated vasculitis in an adolescent.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceRituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.Investigational drugs in thrombotic thrombocytopenic purpura.Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.How I treat refractory thrombotic thrombocytopenic purpura.Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasmaRisk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Thrombotic thrombocytopenic purpura (TPP) successfully rescued by plasma exchange in the ICU: A report of two cases.Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.
P2860
Q24620546-9007CA5F-1688-4B31-99D8-A0F7D7483A6FQ24651320-3E48B524-1A61-439C-9B18-D3993D8BFA70Q28083264-7DE59B99-4E99-4C8F-B22E-159BB810DAFBQ33159947-DAB10028-110A-446A-A0A7-B822BEB139ADQ33327295-3EFC6C1C-5DF4-4FDC-8BCD-E36FBB8E36CAQ33374597-41C2FE1E-1EA9-469A-8619-376923260D91Q33376401-9F3B1EA8-3C28-43CD-93CB-18FA276FC258Q33377500-DF2081D1-64C7-4A54-850A-60A864201C72Q33377517-2E33ADF2-CFBC-4D98-A3EA-F76FA65D66C3Q33380771-516A94DA-5E21-428F-802E-E3A26873EC56Q33389392-475BF071-EDF7-4CCA-930B-2377BFDD852FQ33389561-8ED567A0-84BA-4632-A07F-9EE2C6BEC5CDQ33395696-AAD69944-F8B7-4633-AD73-C34146C24712Q33397081-8D0B20F7-14E6-46DC-92D2-A8DD134FC114Q33400172-2917AFCC-5790-474D-9E0A-AE09C75D27F8Q33401197-EFEB5457-6F6E-4F7A-88E0-803ADA4A5C34Q33401403-AE3D8789-3C66-436C-B0D0-E1EC2A5706B4Q33401647-BD5D6D36-2BF1-494A-88B0-0BE9DC1606E7Q33406040-BF568577-AC80-472F-A285-8034CA7F0B32Q33406785-F5943E6E-6D67-4F0F-B4A1-83BCED68BD45Q33408427-3A3030B0-A2C5-4064-BDC6-7BE009D1AD72Q33421268-6670E726-0052-416C-B161-B2EE9A799820Q33423510-60E93F80-1429-4FF5-8127-50EE388520C4Q33426998-7A0F391C-B89D-4B00-AC62-DD18BAA3AB47Q33427651-3349F0BD-3701-46CD-AEC2-8B3F7C6B138BQ33427885-DD606995-74A5-44C5-B900-4DA2642854CEQ33436972-53016212-46E7-4463-9950-D52A3E1F3AA4Q33443111-63F87E50-47FF-4C95-A105-57B30E7513E2Q39653086-4C0F2B24-AADF-4D8B-BF2F-B21691B304F6Q52576561-23A7A444-0E5F-4F8D-8108-508ADAB1FFA7
P2860
Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@ast
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@en
type
label
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@ast
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@en
prefLabel
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@ast
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P1476
Prognostic value of inhibitory ...... otic thrombocytopenic purpura.
@en
P2093
A Veyradier
B Schlemmer
D Bordessoule
E Boulanger
P2860
P356
10.1111/J.1365-2141.2005.05837.X
P407
P577
2006-01-01T00:00:00Z